Skip to main content
. 2019 Mar 19;2(1):69–81. doi: 10.20517/cdr.2018.20

Figure 2.

Figure 2

Mechanism of anticancer activity of anti-EGFR mAbs. Cetuximab and panitumumab bind to EGF receptors, thus preventing further signalling transduction via PI3K/mTOR and RAS/ERK pathways. Inactivation of growth signalling pathways prevents cell proliferation and survival. EGFR: epidermal growth factor receptor; mAbs: monoclonal antibodies